BiopharmaTrend.com

Cambridge Cancer Genomics

Cambridge Cancer Genomics

Private company
CAMBRIDGE CANCER GENOMICS

Cambridge Cancer Genomics is using blood tests to guide smarter cancer therapy. Currently, cancer patients have to wait up to 6 months to know whether their chemotherapy is working. In the interim, patients suffer the side effects of such treatments. Using simple blood draws, CCG shortens the time required to know whether treatment is working, buying the clinician more time to alter treatment and reduce unnecessary side effects. In addition, we can identify relapse an average of 7 months earlier than standard practice. Over time, CCG will be able to better predict the best therapeutic strategy for cancer patients before they even begin treatment.


Founded
2016
Status
Private company
Geography
United Kingdom based
Funding
$4.120 M
Website
http://ccg.ai/

Products

No products posted yet

Services

No services posted yet


This data is part of our proprietary analytics report:

This service is currently only supported on the desktop screens, please, use this service from your desktop or laptop for correct visualization and functionality

Go to home page